CARB-X, a global non-profit partnership, is granting United States-based VenatoRx Pharmaceuticals up to USD4.1m in non-dilutive funding, with the possibility of up to an additional USD8.9m if certain project milestones are met, to produce a new class of oral antibiotics intended to treat infections caused by multi-drug-resistant (MDR) Neisseria gonorrhoeae, it was reported yesterday.
VenatoRx is producing an oral penicillin-binding protein inhibitor to address the increasing problem of resistance in Neisseria gonorrhoeae to the last resort antibiotic for outpatient use, ceftriaxone. It has identified non-beta-lactam transpeptidase inhibitors that are rapidly bactericidal, impervious to beta-lactamases, and indicate promising selective activity against gonococci, including both wild-type strains and isolates with PBP variants that confer ceftriaxone resistance. This funding is intended to help VenatoRx to progress these early molecules from hit-to-lead through IND-enabling studies.
CARB-X is investing up to USD500m between 2016-2021 to support the development of new antibiotics, rapid diagnostics, vaccines and other life-saving products. The aim is to support projects through the early phases of development, through Phase one for therapeutics, so that they will attract additional private or public support for further clinical development and approval for use in patients.
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
AstraZeneca announces US approval for Ultomiris for NMOSD treatment